According to bluebird bio 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.904804. At the end of 2022 the company had a P/E ratio of -1.93.
Year | P/E ratio | Change |
---|---|---|
2022 | -1.93 | 131.22% |
2021 | -0.8360 | -70.32% |
2020 | -2.82 | -29.08% |
2019 | -3.97 | -34.04% |
2018 | -6.02 | -60.01% |
2017 | -15.1 | 166.04% |
2016 | -5.66 | -34.68% |
2015 | -8.67 | -74.04% |
2014 | -33.4 | 640.36% |
2013 | -4.51 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
Sanofi SNY | 14.7 | -1,719.81% | ๐ซ๐ท France |
Merck MRK | 69.7 | -7,805.08% | ๐บ๐ธ USA |
Sangamo Therapeutics
SGMO | -0.3424 | -62.16% | ๐บ๐ธ USA |
Acceleron Pharma XLRN | N/A | N/A | ๐บ๐ธ USA |
GlycoMimetics
GLYC | -2.85 | 215.41% | ๐บ๐ธ USA |
BioMarin Pharmaceutical BMRN | 117 | -13,044.68% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.